Looking to publish in BioDrugs? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Existing customer loginBioDrugs is a hybrid journal covering the development and therapeutic application of biotechnology-based pharmaceuticals and diagnostic products for the treatment of human disease, serving R&D professionals and clinicians interested in biologic therapies.
Looking to publish in BioDrugs? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Existing customer loginSubmission Instructions
BioDrugs accepts the following article types. Click on an article type to view submission instructions.
Review Article
Systematic Review
Original Research
Narrative Reviews
Meta-Analysis
Summary Of Research Articles (Sras)
Letter To The Editor
Recent Publications
Comparison of the Risk of Acute Anterior Uveitis Flare Between Adalimumab and Subcutaneous Infliximab in Patients with Radiographic Axial Spondyloarthritis and Prior Acute Anterior Uveitis: A Randomized Controlled Trial
Oh Chan Kwon, Soo Min Ahn, Seokchan Hong, Yeon Hong Seo, Min Kim, Joo Yong Lee, Un Chul Park, Seong Joon Ahn, Min-Chan Park, Eun Young Lee, Tae-Hwan Kim, Yong-Gil Kim
Targeting CD38 Across Autoimmune and Plasma Cell–Driven Immune-Mediated Diseases: Rationale, Clinical Evidence, and Emerging Therapeutic Landscape
Dario Roccatello, Savino Sciascia, Daniela Rossi, Roberta Fenoglio
Clinical Outcomes After Week-12 Response-Guided Secukinumab Discontinuation in Psoriasis: A Prospective Real-World Cohort Study
Xin Ma, Yue Jiang, Dongmei Liu, Quanruo Xu, Fanlingzi Shen, Zhen Duan, Xiangjin Gao, Xiuqi Zhang, Ruiqi Cai, Rui Zhang, Bin Li, Ruiping Wang
Population Pharmacokinetic Comparability of CT-P16 Versus EU-Avastin® and US-Avastin® in Healthy Subjects and Patients with Non-Squamous Non-Small Cell Lung Cancer
Taekyung Kim, Heungjo Kim, Hongjae Lee, Keumyoung Ahn, Taehong Park, Hyungseok Baek, Min Jung Chang
Expanding Patient Access to Advanced Therapies
Elena Guillen, Ana Hidalgo-Simon
Frequently asked questions
How long does it take to publish?
Accepted articles are published online after receipt of the corrected proofs.
Reformat to BioDrugs using Livewrite PremiumIs a cover letter required?
A cover letter is used when unpublished material is included in the manuscript and when suggesting reviewers the corresponding author should include reviewer identity details in the submission letter.
Reformat to BioDrugs using Livewrite PremiumWhat are the publication costs?
Open access APC: £3790.00 GBP / $5490.00 USD / €4490.00 EUR. Subscription publishing has no APC charges.
Reformat to BioDrugs using Livewrite Premium